---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-236039"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2024-10-10T23:59:59+00:00"
generated_at: "2026-05-30T16:46:37.546399+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Inhibikase raises ~$110M in private placement; appoints four new directors

## Summary
- Gross proceeds ~$110M from common stock, pre-funded warrants, and Series A-1/B-1 warrants at $1.37 per share unit.
- Company to seek stockholder approval to increase authorized shares; meeting within 90 days of close of offering.
- Board expands from 5 to 7; appoints Bellini, Munshi, Kush, Canner effective Oct 21.
- Series A-1 warrants ($1.37) expire 30 days after Phase 2b safety readout; Series B-1 ($1.49) after efficacy readout.
- New directors invest alongside: BSquared $2M, Munshi family $500K, Kush trust $200K, Soleus Capital ~$21.5M.

## SEC filing metadata
- accession: 0001193125-24-236039
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2024-10-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.02, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312524236039/0001193125-24-236039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312524236039/d882121d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-236039
- JSON: https://secwatch.observer/filing/0001193125-24-236039.json
- Plain text: https://secwatch.observer/filing/0001193125-24-236039.txt

## Key facts
- Executive change
  David Canner was appointed as Class II Director at Inhibikase Therapeutics, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: Amit Munshi and David Canner to serve as Class II directors of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312524236039/0001193125-24-236039-index.htm
- Executive change
  Roberto Bellini was appointed as Class I Director at Inhibikase Therapeutics, Inc..
  - Action: appointed
  - Role: Class I Director
  source text: the Board will appoint Roberto Bellini to serve as a Class I director of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312524236039/0001193125-24-236039-index.htm
- Executive change
  Amit Munshi was appointed as Class II Director at Inhibikase Therapeutics, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: Amit Munshi and David Canner to serve as Class II directors of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312524236039/0001193125-24-236039-index.htm
- Executive change
  Arvind Kush was appointed as Class III Director at Inhibikase Therapeutics, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: Arvind Kush to serve as a Class III director of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312524236039/0001193125-24-236039-index.htm
- Executive change
  Roberto Bellini was elected as Chairperson of the Board at Inhibikase Therapeutics, Inc..
  - Action: elected
  - Role: Chairperson of the Board
  source text: It is expected that the Board will elect Mr. Bellini as Chairperson of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312524236039/0001193125-24-236039-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.